Next Article in Journal
Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’
Next Article in Special Issue
Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs)
Previous Article in Journal
Cell-Penetrating Penta-Peptides (CPP5s): Measurement of Cell Entry and Protein-Transduction Activity
Previous Article in Special Issue
Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(12), 3614-3628;

Pharmacogenetics of SSRIs and Sexual Dysfunction

Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood St. Rm. 164 (M/C886), Chicago, IL 60612, USA
Author to whom correspondence should be addressed.
Received: 1 November 2010 / Revised: 30 November 2010 / Accepted: 9 December 2010 / Published: 15 December 2010
(This article belongs to the Special Issue Antidepressants)
Full-Text   |   PDF [74 KB, uploaded 15 December 2010]


Sexual dysfunction (SD) is a common and disconcerting side effect of selective serotonin reuptake inhibitors (SSRIs) that often influences a patient’s desire to continue long-term antidepressant treatment. Studies specifically assessing changes in sexual well-being over time illustrate that the incidence of sexual side effects from SSRIs ranges from 20% to 70%, depending on the characteristics of the study sample assessed. Developing strategies to predict who may be at the highest risk for adverse changes in their sexual well-being is an important step in improving the quality of life and treatment of patients who require antidepressant therapy. Pharmacogenetic studies of SSRI-associated SD have identified associations between serotonin and glutamate system genes with aspects of SD. The results of studies investigating genetic variations in drug metabolism enzymes and their relationships to antidepressant-associated adverse effects have been mixed. Continued efforts to characterize the relationships between genetic markers and antidepressant outcomes, and to translate this knowledge to patient care, have the potential to significantly improve the empiric selection of antidepressant agents and to minimize the risk for intolerable side effects. View Full-Text
Keywords: SSRI; sexual dysfunction; polymorphism; serotonin; glutamate; drug metabolism; depression SSRI; sexual dysfunction; polymorphism; serotonin; glutamate; drug metabolism; depression
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Osis, L.; Bishop, J.R. Pharmacogenetics of SSRIs and Sexual Dysfunction. Pharmaceuticals 2010, 3, 3614-3628.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top